VIDEO: Durvalumab may improve long-term outcomes in triple negative breast cancer
In this video, Erica L. Mayer, MD, MPH, an assistant professor of medicine at Harvard Medical School and a director of clinical research at Dana-Farber Cancer Institute, discussed results from the phase 2b GeparNuevo trial presented at ASCO 2021.
Study investigators reported that durvalumab (IMFINZI; AstraZeneca), when used in addition to neoadjuvant chemotherapy, improved long-term outcomes in patients with triple negative breast cancer. Previously presented findings from the study showed that this treatment option results in “modest” increase in pathological complete response and slight improvement in event-free survival.
“This more mature analysis from this phase 2 study was looking primarily at longer-term survival outcomes, including disease-free survival, distant disease-free survival and overall survival,” Mayer said. “And interestingly, there seem to be a fairly strong trend toward improvement in all of those endpoints with the addition of durvalumab.”
She added that the findings presented were “very early data from a small study, and there are several other larger studies that are looking at a very similar question — most notably, KEYNOTE 522, where we await similar long-term event-free survival data to see if this is truly a real thing.”
Collapse
Read more about